Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in 2022, is projected to grow at a CAGR of 40.2%, reaching USD 173.55 billion by 2029.
AI facilitates optimal drug candidate identification, offers unprecedented insights into various diseases, and efficiently manages extensive patient datasets. These capabilities are instigating transformative changes across the pharmaceutical landscape.
According to McKinsey, integrating AI capabilities into big data strategies can generate an annual value of up to $100 billion within the US healthcare system. It involves utilizing predictive modeling and thoroughly analyzing sensor data.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
